News Sentiment

BTAI sentiment intelligence

BioXcel Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 0.82 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-40.8% over one week, -28.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

BioXcel Therapeutics (BTAI) Registration Filing Summary

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction -40.8% Price reacting lower
Trend fit Trend inactive -28.3% over four weeks
Fair value -96.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 35
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
Market source 7
TradingView 5
Investing.com 5
Quartr 3
GlobeNewswire 3
Hartford Business Journal 3
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 10
Regulatory and legal 2
Balance sheet 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Quartr Direct company coverage

BioXcel Therapeutics (BTAI) Registration Filing Summary

This summary details BioXcel Therapeutics' (BTAI) registration filing, outlining its business model focused on neuroscience and immuno-oncology using AI platforms. It highlights the company's lead asset, BXCL501 (IGALMI), approved for acute agitation, and discusses recent financi

Tone
Negative 33/100
Event
Market update
Published
14 Jul 2026 02:47
Source
Quartr
Quartr Direct company coverage

BioXcel Therapeutics (BTAI) Q2 2024 earnings summary

BioXcel Therapeutics (BTAI) reported a Q2 2024 net revenue of $1.1M, a 141% increase year-over-year, driven by IGALMI. The company significantly reduced operating expenses and narrowed its net loss to $8.3M, but faces substantial doubt about its ability to continue as a going con

Tone
Negative 39/100
Event
Earnings
Published
13 Jul 2026 14:10
Source
Quartr
Quartr Direct company coverage

BioXcel Therapeutics (BTAI) Q4 2025 earnings summary

BioXcel Therapeutics (BTAI) reported its Q4 2025 earnings, highlighting a submitted sNDA for IGALMI's at-home use with potential approval by year-end 2026 and continued expansion of BXCL501 clinical programs. Financially, the company saw a significant drop in IGALMI net revenue y

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 11:10
Source
Quartr
Stock Titan Direct company coverage

BioXcel (NASDAQ: BTAI) eases liquidity covenant and defers $9M loan payment

BioXcel Therapeutics has amended its loan agreement with Oaktree to gain flexibility on debt payments and liquidity covenants, including deferring a $9 million principal payment. The agreement capitalizes accrued interest through June 30, 2026, defers a June 30 principal payment

Tone
Negative 33/100
Event
Balance sheet
Published
06 Jul 2026 09:40
Source
Stock Titan
Finviz Direct company coverage

BTAI - BioXcel Therapeutics Inc Options

This article provides a detailed financial overview of BioXcel Therapeutics Inc (BTAI), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider and institutional ownership, and short inte

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 11:40
Source
Finviz
Finviz Direct company coverage

BTAI - BioXcel Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filing information for BioXcel Therapeutics Inc (BTAI), including real-time stock performance data, financial metrics, and company statistics. It details key financial ratios, insider and institutional ownership, and volume and volatility indi

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 02:39
Source
Finviz
TradingView Direct company coverage

Price to sales forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI

This article provides access to the "Price to sales forward" financial metric for BioXcel Therapeutics, Inc. (NASDAQ: BTAI) on the TradingView platform. It indicates that the market is currently closed with no trades. The content is primarily a navigation and copyright informatio

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 00:09
Source
TradingView
marketscreener.com Direct company coverage

BioXcel Therapeutics, Inc.(NasdaqCM: BTAI) added to Russell Microcap Index

BioXcel Therapeutics, Inc. (BTAI) has been added to the Russell Microcap Index. The biopharmaceutical company utilizes artificial intelligence to develop medicines in neuroscience and immuno-oncology, with lead candidates BXCL501 for agitation and BXCL701 for aggressive cancers.

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 05:42
Source
marketscreener.com
TradingView Direct company coverage

Price to book forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI

This article provides financial data for BioXcel Therapeutics, Inc. (NASDAQ: BTAI), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section from a financial data platform like TradingView, indicating specific financial metrics for t

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 08:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of BioXcel Therapeutics, Inc. – NASDAQ:BTAI

This article provides financial information for BioXcel Therapeutics, Inc. (NASDAQ: BTAI), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of the data capture, with no trades reported. The information is presented

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

BioXcel Therapeutics, Inc. Actuals & Estimates (FWB:BX20)

This article provides an overview of BioXcel Therapeutics, Inc. (FWB:BX20) financial data and analyst estimates, including income statement, balance sheet, and cash flow. It details stock forecasts, historical price movements, recent earnings, revenue figures, and employee count.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 17:39
Source
TradingView
TradingView Direct company coverage

BioXcel Therapeutics, Inc. Actuals & Estimates (NASDAQ:BTAI)

This article provides an overview of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) stock performance, actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report dates. The article also co

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:39
Source
TradingView
Stock Titan Direct company coverage

BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain

BioXcel Therapeutics, Inc. (BTAI) CFO Richard I. Steinhart exercised derivative awards on June 15, 2026, acquiring 35 shares of Common Stock from Restricted Stock Units (RSUs). This transaction increased his direct Common Stock holdings to 26,335 shares, while 212 RSUs remain. Th

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 16:39
Source
Stock Titan
Stock Titan Direct company coverage

BioXcel Therapeutics (BTAI) CSO converts 35 RSUs, now holds 26,210 shares

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, converted 35 Restricted Stock Units (RSUs) into common shares on June 15, 2026. This transaction increased his direct holdings to 26,210 common shares, with 212 RSUs remaining from an original grant of 562 units on Marc

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 00:09
Source
Stock Titan
Stock Titan Direct company coverage

BioXcel Therapeutics (NASDAQ: BTAI) officer converts RSUs into Common Stock

Javier Rodriguez, an officer at BioXcel Therapeutics (NASDAQ: BTAI), converted 35 Restricted Stock Units (RSUs) into 35 shares of Common Stock on June 15, 2026, at a price of $0.00 per share. This was a vesting-related derivative exercise, not an open-market purchase. Following t

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 00:09
Source
Stock Titan
TradingKey Direct company coverage

BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioXcel Therapeutics Inc (BTAI), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over recent quarters, and recent shareholder activity. The information h

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
TradingKey
TradingKey Direct company coverage

BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of BioXcel Therapeutics Inc (BTAI) stock's dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and lists several upcoming merger-related stock splits scheduled for February 6, 20

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 21:09
Source
TradingKey
Stocktwits Direct company coverage

BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment?

BioXcel Therapeutics (BTAI) saw its stock increase by 5% after announcing positive Phase 2 results for its opioid withdrawal treatment, BXCL501. The drug significantly reduced withdrawal symptoms by over 30% and showed a favorable safety profile, performing comparably or better t

Tone
Positive 80/100
Event
Earnings
Published
06 Jun 2026 11:39
Source
Stocktwits
MSN Direct company coverage

What makes BioXcel Therapeutics (BTAI) a new buy stock

The article provides insights into why BioXcel Therapeutics (BTAI) has been designated as a "new buy" stock. It highlights key factors and recent developments that are attracting investor interest in the company. The analysis likely covers the company's financial health, product

Tone
Positive 77/100
Event
Market update
Published
03 Jun 2026 12:39
Source
MSN
TMX Newsfile Direct company coverage

BioXcel Shareholder Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and is reminding investors of the upcoming September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The investigation follows a sign

Tone
Negative 20/100
Event
Regulatory and legal
Published
02 Jun 2026 11:39
Source
TMX Newsfile
GlobeNewswire Direct company coverage

BioXcel Therapeutics Presents New Data from SERENITY

BioXcel Therapeutics announced new positive data from its Phase 3 SERENITY At-Home trial for BXCL501, showing its effectiveness in reducing agitation across all baseline severity levels in patients with bipolar disorders or schizophrenia. The company presented these findings at t

Tone
Positive 80/100
Event
Market update
Published
29 May 2026 09:10
Source
GlobeNewswire
www.marketscreener.com Direct company coverage

BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics announced positive new data from its Phase 3 SERENITY At-Home trial for BXCL501 (sublingual dexmedetomidine), designed to treat agitation associated with bipolar disorders or schizophrenia in an at-home setting. The analyses showed that BXCL501 significantly

Tone
Positive 86/100
Event
Market update
Published
28 May 2026 12:09
Source
www.marketscreener.com
ChartMill Direct company coverage

BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI)

This article provides recent news and financial updates for BioXcel Therapeutics Inc. (NASDAQ: BTAI). Key updates include the company's Q1 loss and missed revenue estimates as reported by Zacks, as well as BioXcel's own business update and Q1 2026 financial results. The stock 'BT

Tone
Negative 28/100
Event
Earnings
Published
28 May 2026 08:09
Source
ChartMill
Moomoo Direct company coverage

BioXcel Therapeutics | 424B5: Prospectus

This document is a prospectus, specifically a 424B5 filing from BioXcel Therapeutics. These filings are used to register securities with the SEC and provide essential information to potential investors about the offering. The content would detail the terms of the offering, compan

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 01:09
Source
Moomoo
Investing.com Nigeria Direct company coverage

BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com

Vimal Mehta, CEO of BioXcel Therapeutics (NASDAQ:BTAI), sold 19,419 shares of company stock worth $21,108 on May 20, 2026, stemming from the vesting of restricted stock units. This transaction was executed under a Rule 10b5-1 trading plan to cover tax obligations. Despite the sal

Tone
Negative 41/100
Event
Market update
Published
24 May 2026 06:09
Source
Investing.com Nigeria
Stock Titan Direct company coverage

BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, recently engaged in equity compensation activities. He exercised 17,500 Restricted Stock Units (RSUs) on May 4, 2026, and subsequently sold 6,845 common shares on May 20, 2026, at a weighted average price of $1.085 per

Tone
Neutral 50/100
Event
Market update
Published
23 May 2026 22:39
Source
Stock Titan
Investing.com Nigeria Direct company coverage

BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com

BioXcel Therapeutics' Chief Legal Officer, Javier Rodriguez, recently sold $7,111 worth of company stock to cover taxes related to restricted stock unit vesting. The transactions were executed under a Rule 10b5-1 trading plan. The stock is currently trading near its 52-week low,

Tone
Neutral 50/100
Event
Market update
Published
23 May 2026 10:40
Source
Investing.com Nigeria
Investing.com Direct company coverage

BioXcel Therapeutics chief legal officer sells $7,111 in stock

Javier Rodriguez, Chief Legal Officer at BioXcel Therapeutics, Inc. (NASDAQ:BTAI), recently sold $7,111 worth of company stock to cover taxes associated with restricted stock unit vesting. These transactions occurred as BTAI trades near its 52-week low. The company is also workin

Tone
Neutral 50/100
Event
Market update
Published
23 May 2026 05:09
Source
Investing.com